Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases

Medical Mycology

Volumn 41, Issue 2, 2003, Pages 167-170

  Blanco, M T ^a   Hurtado, C ^a   Perez Giraldo C ^a   Moran F J ^a   Gonzalez Velasco C ^a   Gomez Garcia A C ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Facultad de Medicina   (Spain)

Author keywords

Candida albicans; Inhibitory effect; Ritonavir; Saquinavir

Indexed keywords

ASPARTIC PROTEINASE; BOVINE SERUM ALBUMIN; CARBON; NITROGEN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; ENZYME RELEASE; FUNGUS GROWTH; GROWTH INHIBITION; GROWTH RATE; IN VITRO STUDY; NONHUMAN; YEAST; DRUG EFFECT; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM;

BOVINAE; CANDIDA ALBICANS;

ASPARTIC ENDOPEPTIDASES; CANDIDA ALBICANS; CULTURE MEDIA; HIV PROTEASE INHIBITORS; RITONAVIR; SAQUINAVIR;

EID: 0142170023     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.41.2.167.170     Document Type: Article

References (19)

1. Cassone A, De Bernardis F, Torosantucci A, et al. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 448-453.
2. Hood S, Bonington A, Evans J, et al. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS 1998; 12: 447-448.
3. Diz P, Ocampo A, Iglesias I, et al. Lack of ritonavir antifungal effect in vitro. Antimicrob Agents Chemother 1999; 43: 997.
4. Gottfredsson M, Cox GM, Indridason ÓS, et al. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999; 180: 534-537.
5. Klein RS, Arnsten JH, Sobel JD. Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181: 812.
6. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard. vol. 17, no 9. Document M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa., 1997.
7. Cassone A, De Bernardis F, Mondello F, et al. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987; 156: 777-783.
8. Rüchel R, Tegeler R, Trost M. A comparison of secretory proteinases from different strains of Candida albicans. Sabouraudia 1982; 20: 233-244.
9. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
10. Blanco MT, Pérez-Giraldo C, Blanco J, et al. In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method. Antimicrob Agents Chemother 1992; 36: 898-901.
11. Hube B, Sanglard D, Odds FC, et al. Gene disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect Immun 1997; 65: 3529-3538.
12. Cutler JE. Putative virulence factors of Candida albicans. Annu Rev Microbiol 1991; 45: 187-218.
13. Chaffin WL, López-Ribot JL, Casanova M, et al. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol. Mol Biol Rev 1998; 62: 130-180.
14. Borg-von Zepelin M, Meyer I, Thomssen R, et al. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 1999; 113: 747-751.
15. Korting HC, Schaller M, Eder G, et al. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-Infected patients. Antimicrob Agents Chemother 1999; 43: 2038-2042.
16. Monod M, Borg-von Zepelin M, Telenti A, et al. The inhibition of Candida albicans secreted aspartic proteases by three different HIV protease inhibitors. Dermatology 1999; 198: 412-414.
17. Gruber A, Speth C, Lukasser-Vogl E, et al. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999; 41: 227-234.
18. Gottfredson M, Cox GM, Perfect JR. Reply to: Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. J Infect Dis 2000; 181: 812-813.
19. Diz Dios P, Ocampo A, Otero A, et al. Changes in oropharyngeal colonization and infection by Candida albicans in human immunodeficiency virus-infected patients. J Infect Dis 2001; 183: 355-356.